Complement Dependent Cytotoxicity (CDC) is a well characterized effector function of antibodies. Binding of a mAb to its target on the surface of a cell and to C1q through the Fc portion activates and recruits the complement cascade resulting in the formation of the membrane attack complex and subsequent target cell death.
The ability for an antibody therapeutic to activate complement and perform CDC should be evaluated during product characterization.
A Platform For Success
Our team has developed a robust platform methodology to partner with you to qualify and measure CDC activity for a range of targets. Our methods are ready to run for these targets and are also fully customizable for new targets. Both rabbit and human complement can be sourced for CDC assay development and testing.
Contact our expert scientists today to discuss how we can support your unique process with our range of analytical services.